Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study.

"Declarations Ethics approval and consent to participateThis study complied with all laws regarding patient privacy. No direct patient contact or primary collection of individual human subject data occurred. Patients enrolled or previously enrolled in the Canadian mepolizumab PSP program were given the opportunity to provide informed consent that allowed their patient-level data to be shared with ICES. This was conducted by the program coordinators via email, phone, or in person. All executed versions of the consent form and study protocol were approved by an Institutional Review Board (IRB; Pro00034156). These were first approved in June 2019 and continually reviewed every 12 months by the IRB. Consent for publicationNot applicable. Competing interestsKRC received funding from GSK to advise on this study. KC, KU, and EA are employees of, and shareholders in, GSK. CLF, SG, and BM are employees of IQVIA, which received funding from GSK to complete this study. CL received funding from GSK to advise on this study and, outside of the submitted work, reports personal fees and/or research grants from AstraZeneca, Covis Pharma, GSK, Novartis, Sanofi Genzyme, Teva, and Valeo. Competing interests KRC received funding from GSK to advise on this study. KC, KU, and EA are employees of, and shareholders in, GSK. CLF, SG, and BM are employees of IQVIA, which received funding from GSK to complete this study. CL received funding from GSK to advise on this study and, outside of the submitted work, reports personal fees and/or research grants from AstraZeneca, Covis Pharma, GSK, Novartis, Sanofi Genzyme, Teva, and Valeo."

"Funding This study was funded by GSK (study 211271; https://www.gsk-studyregister.com/en/trial-details/?id=211271)."